Audit: QRS - Coffee for Health & Longevity
Audit conducted on 03/09/2026 02:15 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) x 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER; all trace to ER text (e.g. stop items to lines 389-403 and 367, protocol cells to lines 429-437, markers to the ER table lines 522-534). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Hedges carried over: marker_9_why keeps “Kidney association unresolved” (ER line 530); time_2_sub keeps “never demonstrated over a short course” (ER line 488). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found. “Pregnancy beyond 200 mg caffeine daily (about 2 cups)” matches ER line 389; “until controlled”, “until cardiac rehabilitation clearance” retained. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | No Benefit- or Risk-Modifying Factor is surfaced as a gate. Adenosine/dipyridamole stress testing sits under Contraindications, which the ER itself labels “Absolute contraindication” (line 367). |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, study citations, expert names, NCT identifiers or brand names anywhere in the QRS (verified by search). |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind appear in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Register matches the ER: observational findings stated as associations, trial findings as demonstrated effects. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert, objective and data-driven throughout; targets and thresholds given without alarmism. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents thresholds and observations; no prescriptive instruction in the QRS’s own voice. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No clinical directives. The gate items name populations and exposures rather than instructing the reader. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Content presents information (labels, values, targets) rather than recommending or advising. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address anywhere in the file (verified by search for you/your/yours). |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language used where the ER allows it (e.g. “Extra heartbeats from the lower chambers” rather than premature ventricular contractions); remaining technical terms are ER labels required verbatim by 4.2. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every item is a single condensed clause; no elaboration or restatement. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address to the reader. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing assumes a proactive optimiser: brewing method, timing and biomarker targets rather than generic moderation advice. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Assumes willingness to change brewing method, shift timing and monitor 13 biomarkers. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not general-population framing; content is protocol- and measurement-led. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Risk/benefit weighting mirrors the ER’s audience-relevant split (unfiltered-brew cholesterol rise and sleep cost given High tier alongside the benefit tiers). |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” phrasing anywhere; the header uses “Longevity” per the ER canonical topic. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terminology used throughout (“myocardial infarction”, “intraocular pressure”, “analgesics”); the colloquial-sounding “racing-heart sensation” is ER wording (line 542). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: * Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” * Gate headings: “Contraindications”, “Key Interactions” * Tier labels: “High”, “Medium”, “Low”, “Speculative” * Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings and labels are byte-identical to the template: Protocol, Time to effect, Benefits, Risk & Side Effects, Monitoring, Qualitative Assessment, Contraindications, Key Interactions, High/Medium/Low/Speculative, Marker/Target/Why. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 distinct template spans are present; marker_#* and qualitative_item# are correctly expanded to numbered instances (13 marker rows, 6 qualitative items). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A normalised diff of the QRS against the template with all span contents masked shows the metadata comment as the only difference; CSS, comments, footer disclaimer and the website=”…” spans are unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section relevant to the QRS is empty — every mapped ER section (Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Therapeutic Protocol, Monitoring) is populated. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | ER bold labels reused verbatim as protocol labels: “Standard intake”, “Preferred preparation”, “Best time of day” (ER lines 429, 431, 437). Marker names match the ER biomarker column. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No invented or paraphrased labels; tier labels and marker names track the ER headings and table. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters in the file (verified by search); the ER’s tier emoji and the “Conflicted” markers were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to single-clause items with no continuation content; no second-page overflow structure was introduced. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment occupies lines 2-14, immediately after <!doctype html> and before any other comment or markup. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” on line 3 and closing “—” on line 13; the preamble text on line 2 sits outside the YAML block. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no element on the sheet surfaces any of these values. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: coffee_2026-0903-0002_Opus_ER.md (line 4). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 (line 5), matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0903-0202 (line 6), correct YYYY-MMDD-HHMM format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus (line 7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 (line 8). |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” = nickname plus version number, no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: coffee_2026-0903-0002_Opus_QRS.html (line 9), matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | No leading or trailing whitespace and no unnecessary quoting on any value. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic = “Coffee for Health & Longevity” (line 417), matching the ER canonical_topic with the ampersand encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | header_subline_date = 09/03/2026 (line 421), the MM/DD/YYYY form of qrs_creation_date 2026-0903-0202. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | header_subline_model = Opus 5 (line 425). |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the template subline; no badge, version stamp, AKA line, source-AI attribution, audit date or variant marker. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER Conclusion paragraphs 1 and 3 (lines 572, 576) into the three-compound-group framing plus the execution point on method, timing and biology. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Exactly 60 words (counted by script). |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion passage: compound groups and their divergent effects to line 572, the method/timing/biology precedence to line 576. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “stimulant group”, “oily group” and “plant-acid group” in place of caffeine/diterpene/chlorogenic-acid terminology; “liver scarring” rather than fibrosis. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No relative risks, effect sizes or confidence intervals. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items derive from the ER Key Interactions & Contraindications section (lines 359-403). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | The ER’s eight “Populations who should avoid Coffee” bullets are all represented (the compound pregnancy bullet on line 389 is split into two items), plus the absolute contraindication on line 367. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Ten <li> elements inside the stop_items span (lines 573-582). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No trailing rationale retained — e.g. the ER’s “where caffeine clearance is severely impaired” is stripped from the Child-Pugh C item (ER line 397). No dash-trailing clauses present. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Qualifiers preserved: “200 mg caffeine daily (about 2 cups)”, “(>=160/100 mmHg), until controlled”, “(>21 mmHg on treatment)”, “Child-Pugh Class C”, “within 90 days”, “abstain >=12 h, preferably 24”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication bullets contain no ranking notation inside parentheses; the only in-paren symbols are numeric thresholds. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is not empty, and the ER does identify populations that should avoid coffee (lines 387-403), so the condition for emptiness does not arise. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty, so no empty-state HTML comment is required. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eleven items derive from the ER Key Interactions & Contraindications bullets (lines 361-385). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All twelve ER interaction bullets are represented except the adenosine/dipyridamole entry, which is correctly carried in Contraindications instead, and L-Theanine, which the ER classes as “No interaction of concern” (line 383). |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eleven <li> elements inside the caution_items span (lines 590-600). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanism, consequence and mitigation sentences are all stripped; only the agent class and its examples remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved in parentheses for every class that has them, and the 65-130 mg per dose threshold is kept for combination analgesics. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets contain no ranking notation inside parentheses; parenthetical content is drug-name lists and a dose range only. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is not empty, and the ER identifies twelve interactions, so the condition for emptiness does not arise. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty, so no empty-state HTML comment is required. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three action sets derive from the ER Therapeutic Protocol section (lines 429, 431, 437). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard intake, preferred preparation and best time of day are the three actionable levers; the remaining ER bullets are competing approaches or modifying factors rather than base actions. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct actionable implementation aspects exist in the ER, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry ER-derived content, e.g. action_1_sub “About 240 mL per cup - the intake with the largest observed risk reduction” from ER line 429. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Acute alerting/performance (ER line 488), the metabolic and liver associations (line 488) and atrial fibrillation recurrence over six months (line 205) are the three time-to-effect facts the ER supplies. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered from the High-tier acute benefit down through the Medium-tier chronic associations, matching the ER’s own evidence weighting. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields carry ER-derived content with values 30-60 minutes, Years and 6 months. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (line 488), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All four tiers map to the ER Expected Benefits section (lines 147-237). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four benefit spans are populated (lines 538-563). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is a bare outcome phrase; no magnitudes, mechanisms or study details carried across. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER’s parenthetical glosses (e.g. “(the main form of primary liver cancer)”, line 187) are stripped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four sub-sections (High, Medium, Low, Speculative) have items in the ER, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All four tiers map to the ER Potential Risks & Side Effects section (lines 257-341). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four risk spans are populated (lines 612-636). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is a bare risk phrase; frequencies, mmHg values and trial descriptions are all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER’s parenthetical glosses (e.g. “(extra heartbeats arising from the heart’s lower chambers)”, line 297) are stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four sub-sections (High, Medium, Low, Speculative) have items in the ER, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The marker table and cadence derive from the ER Monitoring Protocol & Defining Success section (lines 514-534). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 13 quantifiable biomarkers from the ER table (lines 522-534) are present, in ER order, with matching targets. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | monitoring_cadence carries the full recheck schedule condensed from ER line 518 (8 weeks then annually, 12-monthly, 6-12 monthly ferritin, ophthalmologist’s schedule). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | The six qualitative items derive from the ER’s qualitative-marker bullets (lines 538-548). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are listed, none omitted or merged. |
Issues 03/09/2026 02:15
Pass rate 100.00%. No issues found.
Issues 03/09/2026 02:08
- 4.5 — Exceeds the one-A4-page budget: The sheet’s content overruns a single A4 column by roughly 60–70%; the header, at-a-glance, protocol panel, benefits card and the two decision gates (lines 415–623) already fill the page before the risks card, the thirteen-row monitoring table and the six-item qualitative card are laid out.
- 8.5 — Threshold parentheticals not trimmed: Contraindication qualifiers are preserved but written out at full length — line 578 “(systolic at or above 160 mmHg or diastolic at or above 100 mmHg)” and line 581 “eye pressure above 21 mmHg” — rather than trimmed to the compact numeric form the one-page budget requires.
- 9.4 — Mitigation advice carried in interaction items: Line 605 “Levothyroxine (at least 60 minutes between tablet and first cup)” and line 613 “Iron supplements and multivitamins (iron taken an hour before coffee)” carry the ER’s mitigation instruction, which is an elaboration rather than a qualifier determining whether the interaction applies.
Fixes 03/09/2026 02:08
- 4.5 — Sheet condensed toward one A4 page: Trimmed discretionary wording across the protocol sublines, the Medium benefits list, the monitoring targets and rationale, the cadence sentence and the six qualitative items, removing roughly a quarter of the rendered text while keeping every ER-sourced fact, all thirteen biomarkers and all six qualitative markers.
- 8.5 — Threshold qualifiers trimmed to compact form: Replaced “(systolic at or above 160 mmHg or diastolic at or above 100 mmHg)” with “(≥160/100 mmHg)”, “with eye pressure above 21 mmHg on treatment” with “(>21 mmHg on treatment)” and “(abstinence for at least 12 hours, preferably 24)” with “(abstain ≥12 h, preferably 24)”; all thresholds and time windows are retained.
- 9.4 — Mitigation advice removed from interaction items: Stripped “(at least 60 minutes between tablet and first cup)” from the levothyroxine item and “(iron taken an hour before coffee)” from the iron item, leaving just the interacting agent; the named drug lists that determine applicability were kept and shortened.